Metraipolis › archive › dc_0b1ca105da54

Anti-interleukin-6 — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Anti-interleukin-6
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-09T14:16:33.102Z
SHA-256 of the archived text
2b7527066452d6794178275301aa761f68d241a2032a283d3bedfedda5c0e6c7
Stable URL of this page
https://metraipolis.com/documento/dc_0b1ca105da54

How to cite

Anti-interleukin-6 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Anti-interleukin-6 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_0b1ca105da54 (Metraipolis archive dc_0b1ca105da54, sha256 2b7527066452d6794178275301aa761f68d241a2032a283d3bedfedda5c0e6c7)
BibTeX
@misc{dc0b1ca105da54,
  title = {Anti-interleukin-6 — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Anti-interleukin-6},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_0b1ca105da54; sha256 2b7527066452d6794178275301aa761f68d241a2032a283d3bedfedda5c0e6c7},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Anti-interleukin-6. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors. The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. The second, siltuximab (Sylvant), is directed against IL-6 itself. Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8-negative patients with multicentric Castleman's disease. Siltuximab was also tested in the phase I/II study for therapy of patients with metastatic castration-associated prostate cancer in combination with docetaxel and in renal cell carcinoma; phase II trials in ovarian cancer resulted in 39% of patients showed disease stabilization via IL-6-regulated downregulation of CCL2, CXCL12 and VEGF. Tocilizumab was first used in large-cell lung carcinoma. In phase I/II trial of tocilizumab in ovarian cancer EGFR pathway upregulation was observed and after inhibition of this pathway by gefitinib tumor growth was decreased both in vitro and in vivo. Sarilumab was approved by US FDA in 2017 for rheumatoid arthritis. Several agents are in clinical trials: olokizumab (CDP6038) elsilimomab, clazakizumab (BMS-945429, ALD518), sirukumab (CNTO 136), levilimab (BCD-089), and CPSI-2364 an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway. ALX-0061. e.g. for rheumatoid arthritis : clazakizumab, olokizumab, sarilumab and sirukumab have all reported encouraging phase 2 results. Sirukumab is in multiple phase 3 trials. Agents in pre-clinical development include ARGX-109, FE301, and FM101.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Anti-interleukin-6» — https://en.wikipedia.org/wiki/Anti-interleukin-6
Wikidata Q4774187: «drugs to suppress IL-6 signalling» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4774187
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Anti-interleukin-6?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1372997495, consultata il 2026-11-09T14:12:47.882Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 43843032e4508e71f7fbdc1ec6b12b1589dabe1a3daa7ce88f64390a5c4cb538